

Results for announcement to the market		
AFT Pharmaceuticals Limited		
Reporting Period	6 months to September 30 2022	
Previous Reporting Period	6 months to September 30 2021	
Currency	NZ\$	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$65,750	Up 18%
Total Revenue	\$65,750	Up 18%
Net operating profit/(loss) from continuing operations	\$3,457	Down 37%
Total operating net profit/(loss)	\$3,457	Down 37%
Net profit/(loss) after tax from continuing operations	\$1,452	Down 66%
Total Net profit/(loss) after tax	\$1,452	Down 66%
Interim/Final Dividend		
Quoted Equity Securities:		
Amount per Quoted Equity Security	No dividends have been paid on ordinary shares and it is currently not proposed to pay dividends.	
Imputed amount per Quoted Equity Security	Not Applicable	
Record Date	Not Applicable	
Dividend Payment Date	Not Applicable	
Unquoted Equity Securities:		
Amount per Unquoted Redeemable Preference Share	Not Applicable	
Imputed Amount per Unquoted Redeemable Preference Share	Not Applicable	
Record Dates	Not Applicable	
Dividend Payment Dates	Not Applicable	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	\$0.15	\$0.05
A brief explanation of any of the figures above necessary to enable the figures to be understood	Accompanying this announcement are the Group's unaudited consolidated financial statements for the six months ended 30 September 2022. These financial statements and the half year results commentary dated 24 November 2022 provide the balance of information requirements in accordance with NZX Listing Rule 3.5 and Appendix 2.	

	Pursuant to ASX listing rule 1.15.3 AFT Pharmaceuticals Limited confirms that it continues to comply with the rules of its home exchange (NZX Main Board).
Authority for this announcement	
Name of person authorised to make this announcement	Malcolm Tubby
Contact person for this announcement	Malcolm Tubby, Chief Financial Officer, AFT Pharmaceuticals Ltd
Contact phone number	+64 9 488 0232
Contact email address	malcolm@aftpharm.com
Date of release through MAP	24 November 2022

Unaudited financial statements accompany this announcement.